James D. Anderson

Array ( [id] => 19677082 [patent_doc_number] => 12188936 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-01-07 [patent_title] => Biomarkers and therapeutics for endocrine therapy resistance [patent_app_type] => utility [patent_app_number] => 15/734030 [patent_app_country] => US [patent_app_date] => 2019-05-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 20 [patent_no_of_words] => 12216 [patent_no_of_claims] => 35 [patent_no_of_ind_claims] => 9 [patent_words_short_claim] => 61 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15734030 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15848111 [patent_doc_number] => 10639316 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2020-05-05 [patent_title] => Method of treating Parkinson's disease [patent_app_type] => utility [patent_app_number] => 16/426121 [patent_app_country] => US [patent_app_date] => 2019-05-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4370 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 64 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16426121 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17635043 [patent_doc_number] => 11345756 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-05-31 [patent_title] => CCR3 inhibition for ocular angiogenesis and macular degeneration [patent_app_type] => utility [patent_app_number] => 16/425293 [patent_app_country] => US [patent_app_date] => 2019-05-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 3514 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 48 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16425293 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14990847 [patent_doc_number] => 20190314381 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-10-17 [patent_title] => COMPOSITIONS AND METHODS FOR INHIBITION OF MYCOBACTERIA [patent_app_type] => utility [patent_app_number] => 16/422594 [patent_app_country] => US [patent_app_date] => 2019-05-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11413 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 45 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16422594 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16946589 [patent_doc_number] => 20210205280 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-07-08 [patent_title] => COMBINATION THERAPIES FOR TREATING CANCER [patent_app_type] => utility [patent_app_number] => 17/056459 [patent_app_country] => US [patent_app_date] => 2019-05-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19038 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 74 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17056459 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15209523 [patent_doc_number] => 20190367448 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-12-05 [patent_title] => TREATMENT OF SLEEP-WAKE DISORDERS [patent_app_type] => utility [patent_app_number] => 16/420834 [patent_app_country] => US [patent_app_date] => 2019-05-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14432 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16420834 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15848109 [patent_doc_number] => 10639315 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2020-05-05 [patent_title] => Pharmaceutical compositions and methods for treating Alzheimer's disease [patent_app_type] => utility [patent_app_number] => 16/418614 [patent_app_country] => US [patent_app_date] => 2019-05-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5721 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 74 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16418614 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16930789 [patent_doc_number] => 20210196678 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-07-01 [patent_title] => SELECTIVE ANDROGEN RECEPTOR DEGRADER (SARD) LIGANDS AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 17/055988 [patent_app_country] => US [patent_app_date] => 2019-05-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 47658 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -44 [patent_words_short_claim] => 32 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17055988 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16975311 [patent_doc_number] => 20210219548 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-07-22 [patent_title] => USE OF FUNGICIDES AND GLYCINE BETAINE IN COMBINATION FOR CONTROLLING FUNGAL PLANT PATHOGENS [patent_app_type] => utility [patent_app_number] => 17/055377 [patent_app_country] => US [patent_app_date] => 2019-05-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7428 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -51 [patent_words_short_claim] => 27 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17055377 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17052119 [patent_doc_number] => 20210261553 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-08-26 [patent_title] => FUSED TETRAZOLES AS LRRK2 INHIBITORS [patent_app_type] => utility [patent_app_number] => 17/055198 [patent_app_country] => US [patent_app_date] => 2019-05-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 42796 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -98 [patent_words_short_claim] => 1293 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17055198 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15708649 [patent_doc_number] => 20200101090 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-04-02 [patent_title] => USE OF AMINOSALICYLATES IN DIARRHOEA-PREDOMINENT IRRITABLE BOWEL SYNDROME [patent_app_type] => utility [patent_app_number] => 16/407458 [patent_app_country] => US [patent_app_date] => 2019-05-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4468 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -24 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16407458 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15020695 [patent_doc_number] => 20190321352 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-10-24 [patent_title] => H4 AGONIST MOLECULE FOR THE TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS [patent_app_type] => utility [patent_app_number] => 16/401423 [patent_app_country] => US [patent_app_date] => 2019-05-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 2974 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -6 [patent_words_short_claim] => 40 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16401423 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15848107 [patent_doc_number] => 10639314 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2020-05-05 [patent_title] => Method of treating Alzheimer's disease [patent_app_type] => utility [patent_app_number] => 16/398845 [patent_app_country] => US [patent_app_date] => 2019-04-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4335 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 64 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16398845 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14715471 [patent_doc_number] => 20190248799 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-08-15 [patent_title] => CRYSTALLINE FORMS OF A BRUTON'S TYROSINE KINASE INHIBITOR [patent_app_type] => utility [patent_app_number] => 16/393797 [patent_app_country] => US [patent_app_date] => 2019-04-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 37119 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => 0 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16393797 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14715469 [patent_doc_number] => 20190248798 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-08-15 [patent_title] => CRYSTALLINE FORMS OF A BRUTON'S TYROSINE KINASE INHIBITOR [patent_app_type] => utility [patent_app_number] => 16/393775 [patent_app_country] => US [patent_app_date] => 2019-04-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 37118 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -29 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16393775 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16686669 [patent_doc_number] => 20210069144 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-03-11 [patent_title] => ISOTOPICALLY MODIFIED COMPOSITION AND THERAPEUTIC USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/045094 [patent_app_country] => US [patent_app_date] => 2019-04-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9853 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -27 [patent_words_short_claim] => 35 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17045094 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14624483 [patent_doc_number] => 20190225609 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-07-25 [patent_title] => FLUORINATED TETRAHYDRONAPHTHYRIDINYL NONANOIC ACID DERIVATIVES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 16/373780 [patent_app_country] => US [patent_app_date] => 2019-04-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 34171 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 17 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16373780 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14893625 [patent_doc_number] => 20190290578 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-09-26 [patent_title] => STABLE ORAL SOLUTIONS FOR COMBINED API [patent_app_type] => utility [patent_app_number] => 16/374375 [patent_app_country] => US [patent_app_date] => 2019-04-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8348 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -33 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16374375 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15604131 [patent_doc_number] => 10583105 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-03-10 [patent_title] => Compositions and methods for neuroprotection and treatment of neurodegeneration [patent_app_type] => utility [patent_app_number] => 16/371779 [patent_app_country] => US [patent_app_date] => 2019-04-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 4 [patent_no_of_words] => 5769 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 22 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16371779 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16532079 [patent_doc_number] => 10874654 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-12-29 [patent_title] => Increasing expression level of apoptosis-related genes by treating a human subject with a nitroxide [patent_app_type] => utility [patent_app_number] => 16/356949 [patent_app_country] => US [patent_app_date] => 2019-03-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15715 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 108 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16356949 [rel_patent_id] =>[rel_patent_doc_number] =>)